Janux Therapeutics, Inc.
JANX
$16.12
$0.120.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 24.00M | 13.73M | 10.00M | 10.00M | 439.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.00M | 13.73M | 10.00M | 10.00M | 439.00K |
| Cost of Revenue | 123.98M | 127.65M | 125.90M | 115.15M | 99.14M |
| Gross Profit | -99.98M | -113.92M | -115.90M | -105.15M | -98.70M |
| SG&A Expenses | 43.57M | 43.06M | 41.77M | 39.13M | 46.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 167.56M | 170.72M | 167.67M | 154.29M | 145.32M |
| Operating Income | -143.56M | -156.98M | -157.67M | -144.29M | -144.88M |
| Income Before Tax | -102.59M | -114.48M | -113.63M | -101.90M | -105.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -102.59 | -114.48 | -113.63 | -101.90 | -105.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.59M | -114.48M | -113.63M | -101.90M | -105.64M |
| EBIT | -143.56M | -156.98M | -157.67M | -144.29M | -144.88M |
| EBITDA | -141.65M | -155.00M | -155.64M | -142.22M | -142.80M |
| EPS Basic | -1.64 | -1.84 | -1.83 | -1.68 | -1.80 |
| Normalized Basic EPS | -1.03 | -1.15 | -1.15 | -1.05 | -1.12 |
| EPS Diluted | -1.64 | -1.84 | -1.83 | -1.68 | -1.80 |
| Normalized Diluted EPS | -1.03 | -1.15 | -1.15 | -1.05 | -1.12 |
| Average Basic Shares Outstanding | 249.77M | 248.74M | 247.86M | 242.55M | 235.16M |
| Average Diluted Shares Outstanding | 249.77M | 248.74M | 247.86M | 242.55M | 235.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |